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Poster Session II S359There was no difference, however, between MMF and MTX in inci-
dence of grade II-IV aGVHD (pooled RR 5 0.99 (95%CI, 0.83,
1.18; p 5 0.87)), incidence of cGVHD (pooled RR 5 1.01 (95%CI,
0.83, 1.22; p 5 0.95)), relapse risk (pooled RR 5 0.97 (95%CI,
0.68,1.38; p 5 0.86)), NRM (pooled RR 5 0.91 (95%CI, 0.60, 1.37;
p5 0.64)) or OS (pooled HR5 0.83 (95%CI, 0.58, 1.20; p5 0.33)).
Conclusion: critical appraisal of available evidence appears limited/
weak to recommend one particular agent, MMF or MTX, to com-
bine with a calcineurin inhibitor as the preferred aGVHD prophy-
laxis regimen. A large randomized controlled trial that compares
MMF and MTX is needed to address this issue. But, identifying
the most optimal doses and schedules of administration of MMF
and MTX is necessary beforehand.419
THE CNS IN ACUTE GVHD: DEVELOPMENT AND EFFECTS
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Graft-versus-host disease (GVHD) is a severe complication of mul-
tiple organ systems in allogeneic hematopoietic stem cell transplanta-
tion (HSCT). An association between neurological complications and
GVHDhas been reported in patients after allogeneicHSCT. In amu-
rine MHC-disparate allogeneic transplantation model (BM and T
cells from C57BL/6 into lethally irradiated BALB/c) we studied
whether the CNS is a target organ of acute GVHD.
CNS infiltrating lymphocytes were isolated frombrains after com-
plete perfusion of the animals. We found increasing numbers of
CNS-infiltrating donor derived CD4 and CD8 alloreactive T cells
on day 7, 14, and 21 (p\0.001) in brains from allo-HSCT recipients,
but almost none in syngeneic transplanted controls. The majority of
infiltrating lymphocytes were effector memory T cells
(CD44highCD62Llow). P-selectin-glycoprotein-1, Lymphocyte-
function-associated-antigen-1 and a4-Integrin were broadly and
CXCR-3 was less frequently expressed, while Lymphocyte-Peyer-
patch-adhesion-molecule was absent, the latter distinguishing
CNS infiltrating T cells from peripheral T cells.
Histological analysis and immunohistochemistry for CD3 and
CD4 in situ showed infiltration of Cortex, Hippocampus, Basal gan-
glia, Thalamus, Hypothalamus, Cerebellum, andMedulla oblongata
in allogeneicHSCT recipients, consistent with lymphocyticmultifo-
cal meningoencephalitis. Syngeneic transplanted controls showed no
pathology and T cells were virtually undetectable (p\0.01). Apopto-
tic cell death by TUNEL staining was only observed in allogeneic
transplanted controls.
We performed behavioral tests 14 to 20 days after HSCT to test
whether these findings were associated with cognitive deficits. Mice
were tested before the onset of severe GVHD. We found no differ-
ences between allogeneic- versus syngeneic- or non-transplanted
mice in locomotor activity, motor coordination, strength and neuro-
muscular function. However, allogeneic transplanted animals demon-
strated increased anxious behavior and decreased exploratory activity
(p\0.01). Importantly, spatial learning was impaired in allogeneic
transplanted animals as compared to both controls (p\0.0001).
In conclusion, we observed in our experimental GVHD models
that allo-HSCT recipients incur a lymphocytic meningoencephalitis
during the early stages of acute GVHD, which is associated with sig-
nificant infiltration of donor effectormemoryT cells in the CNS and
certain cognitive defects, such as spatial memory loss.420
TEN YEARS EXPERIENCE OF HOME-CARE DURING THE NEUTROPENIC
PHASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION
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After allogeneic hematopoietic stem-cell transplantation (HSCT),
patients living within one and a half hours’ driving distance to the
unit were given the option of treatment at home after HSCT. An ex-
perienced nurse visited the patient every morning and a phone-call
from a physician was given in the afternoon.
One-hundred and forty-six patients treated at home during the
neutropenic phase were compared to matched hospital controls,
coming from outside Stockholm. Because good oral nutrition was
correlated to reduced acuteGVHD, oral intake was intensified in pa-
tients treated in the hospital from September 2006 (new controls).
We compared four groups; old home-care (before September
2006, n 5 76), new home-care (from September 2006, n 5 70),
old (n 5 76) and new controls (n 5 70).
The cumulative incidence of acute GVHDgrades II – IV was 15%
in the old home-care group, which was significantly lower as op-
posed to 32 – 44% in the new home-care group (p\0.001) and the
two control groups (p\0.03). Cumulative incidence of chronic
GVHD was between 35 and 41% in the four groups.
Transplant-related mortality was between 10 and 24% in the
four groups (n.s.). No patient died at home. Relapse probability
was similar in the four groups. Oral nutrition (kcal/kg/day) dur-
ing the first three weeks was significantly worse in the old con-
trols, as opposed to all other groups (p\0.01). Among the old
controls, oral nutrition was median 18.5 kcal/kg/day, as opposed
to 23.6 kcal/kg/day in the new controls (p 5 0.002). Oral nutri-
tion (p 5 0.02) and days at home (p 5 0.005) were correlated to
low grade of acute GVHD. The new home-care patients spent
fewer days at home (p 5 0.002). In multivariate analysis,
GVHD grades 0-I was associated with home care (HR 2.46, p
5 0.02), days spent at home (HR 0.92, p 5 0.005), but not to
oral nutrition (HR 0.98, p 5 0.13). Despite improved oral intake
in patients treated in the hospital more recently, acute GVHD
did not decrease. The old home-care patients had a decreased
risk of acute GVHD, which probably is due to a long time spent
at home.
Five-year survival was 61% in the home-care group as compared
to 49% in the controls (p 5 0.07).
Conclusion: Home care is safe. Home care and many days spent at
home were correlated to a low risk of acute GVHD.421
SYSTEMIC AND HEPATIC THIOL REDOX DYSREGULATION IN GRAFT VER-
SUS HOST DISEASE
Kanathezhath, B.1,2, Shenvi, S.1, Johl, A.1, Manmohan, R.1,
Bhandhal, M.K.3, Oh, D.3, Zhou, A.1, Kuypers, F.A.1,
Walters, M.C.1,2, Ames, B.N.1,3, Suh, J.1 1Children’s Hospital Oakland
Research Institute, Oakland, CA; 2Children’s Hospital and Research Cen-
ter Oakland, Oakland, CA; 3University of California Berkeley, Berkeley,
CA
Graft-versus-host disease (GVHD) is mediated by a series of path-
ophysiological events that follow transplant conditioning and are
amplified by cellular effectors and inflammatory pathways. In addi-
tion, GVHD increases oxidative stress and alters the redox environ-
ment. Whether redox dysregulation in itself potentiates the tissue
injury of GVHD is unknown. We hypothesized that redox pertuba-
tion is a proximal event that precedes target organ injury in GVHD.
To explore this, we appliedmass-spectrometry based thiol redoxme-
tabolomics to analyze the plasma and hepatic sulfur amino acid
(SAA) and thiol oxidation states in several well characterized murine
models of GVHD (Allo) and compared to syngeneic (Syn) controls,
at multiple time-points post-transplantation. Of the 38 amino-acid
metabolites profiled, significant depletion of plasma glutathione
(GSH) redox potential was noted in Allo (-127.36 16mV) compared
to Syn [158.1618 mV (p5 0.04)] mice as early as day +4 post- trans-
plantation. This change in GSH redox state was not reflected in the
cysteine (Cys/CySS) system, the principal redox couple in plasma. By
day +14 post-transplantation, further decline in plasma GSH was
noted in Allo mice while normalization of this metabolite was seen
in Syn controls. The total hepatic GSH concentration in Allo
S360 Poster Session II(43.26 13 nmol/mg proteins) declined by 33% (p5 0.05) relative
to Syn group (686 16 nmol/mg proteins), indicating impaired GSH
synthesis. Additionally, a significant twofold (p5 0.0007) rise in he-
patic homocysteine and ophthalmic acid levels were detected in Allo
mice, linking both SAA and redox metabolic imbalance to GVHD.
To investigate mechanism(s) of GSH redox loss in GVHD, he-
patic mRNA and protein levels of gamma-glutamylcysteine ligase
[GCLC (rate-limiting enzyme)], were quantified. The hepatic
GCLC transcript and protein declined in Allo compared to Syn
mice [GCLC fold change: day +4 5 0.4 vs 1.0360.15; day +10 5
0.36 0.05 vs 1.06 0.05 (p 5 0.0004), respectively]. Target organs
like lungs and gut also revealed depletion of intracellular thiol in
Allo mice that directly correlated with the degree of T cell infiltra-
tion. Together, these data show that the GSH synthetic pathway is
specifically affected in GVHD. The tight transcriptional deregula-
tion of GCLC with depletion of GSH reserve is an early event and
precedes histopathological changes of GVHD. Identification of
modifiers of GCLC/GSH/GSSG system may provide a novel target
for treatment of GVHD.422
RETROSPECTIVE ANALYSIS OF STANDARD VERSUS MINI-DOSE METHO-
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Background: Graft-versus-host disease (GVHD) is one of the
primary contributing factors to morbidity and mortality following
allogeneic stem cell transplantation. Methotrexate (MTX) has
been an integral component of prophylaxis regimens against
acute GVHD when combined with calcineurin inhibitors. Recent
data suggests that lower doses of MTX are effective in prevent-
ing aGVHD and may be associated with less toxicity. However,
few comparative studies have been performed between so called
mini-MTX and standard MTX dosing schemas. The primary ob-
jective of this analysis was to compare the incidence of acute
GVHD with standard versus mini-dose MTX prophylaxis. Sec-
ondary objectives evaluated the safety and the toxicity associated
with MTX administration.
Methods: This retrospective review included allogeneic stem cell
transplant recipients at Memorial Sloan-Kettering Cancer Center
(MSKCC) between 8/1/2003-8/16/2010 that received standard or
mini-MTX as part of post-transplant GVHD prophylaxis. Standard
MTX dosing was defined as 15 mg/m2 on day 1 with subsequent
doses of 10 mg/m2 administered on days 3, 6 and 11. The mini-
MTX group included patients who never received a dose of 15
mg/m2.
Results: 226 patients (138 standard and 88 mini-MTX) were in-
cluded in the analysis. Based on clinical practice at MSKCC,
the standard dose arm had a higher frequency of leukemia patients
while the mini-dose group had a higher frequency of lymphoma
patients. Median age at transplant was 27 years and 50 years for
standard and mini-dose groups, respectively (p\0.001). The me-
dian follow up for patients alive without acute GVHD was 33
months (range 10-90 months). Cumulative incidence of GVHD
at 3 months was 28.9% [95% CI: (21.4-36.6%)] and 28.4%
[95% CI (19.0-37.9%)] for the standard and mini-dose treatment
arms (p 5 0.91). The adult subgroup also revealed no difference
in aGVHD at 3 months (p 5 0.56). A univariate analysis showed
that CMV seropositivity was positively associated with higher
rates of GVHD (HR: 1.81 [95% CI: 1.14-2.85, p 5 0.01). Dose
adjustments or delay of MTX were significantly different between
groups (43.5% in standard arm vs. 15.9% mini-dose arm,
p\0.0001) suggesting an improved toxicity profile, however this
may have been impacted by the primary conditioning regimen.
Conclusion: Prophylaxis with mini-MTX may be associated with
a similar incidence of aGVHD and an improved toxicity profile
when compared to a standard dose schema.423
TRAIL OVER-EXPRESSION ON DONOR T CELLS ENHANCES GVT AND SUP-
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Strategies to suppress GVHD are often associated with broader
suppression of the immune system leading to a compromised
GVT effect. We have demonstrated that genetically engineered T
cells over-expressing TNF-Related Apoptosis Inducing Ligand
(TRAIL) have enhanced GVT effects and explicitly suppress
GVHD. TRAIL induces apoptotic signals through death receptor
(DR) 4 and 5 molecules (only DR5 in mice) expressed on certain tu-
mors and inducible on others. TRAIL is therefore an attractive can-
didate for genetic engineering of donor T cells to enhance their
GVT potential.
Mature T cells derived from donor B6 splenocytes were trans-
duced with a lentiviral TRAIL expression vector. The transduced
TRAIL+ T cells were adoptively transferred into lethally irradiated
CBF1 recipients of T cell depleted allografts and LB27.4 tumor to
assess their GVHD and GVT activity. TRAIL+ T cells displayed
significantly enhanced antitumor immunity compared to mock
(GFP)-transduced controls in vitro and upon transfer into tumor
bearing allo-BMT recipients (p\0.01, 100% survival in TRAIL+
T cell group). Additionally, the recipients treated with TRAIL+ T
cells had significantly less GVHD lethality and morbidity. This
was observed across multiple GVHD models (B6 / CBF1 and
B10.BR/ B6). Using in vitro proliferation assays and in vivo biolu-
minescent imaging, we found that TRAIL+ T cells suppressed pro-
liferation of non-transduced alloreactive T cells. To explore the
factors contributing to TRAIL-mediated suppression of GVHD,
we used recipients deficient in DR5 (DR5ko) and found that
TRAIL+ T cells suppress GVHD by impairing host APC functions.
Precursor (pre)T cells can regenerate the T cell compartment with-
out GVHD. We generated and expanded TRAIL+ preT cells using
the OP9-DL1 co-culture system. Adoptive transfer of B6 TRAIL+
preT cells into syngeneic-transplanted BALB/c mice reconstituted
the T cell compartment with TRAIL+ T cells and caused enhanced
antitumor activity (p\0.05) compared to controls.
Collectively, our data demonstrate that donor T cells genetically
engineered to expressTRAIL can enhanceGVTeffects and suppress
lethal GVHD through impairment of host APCs in recipients of
allo-HSCT. Furthermore, we demonstrated that allogeneic ex vivo
generated preT cells expressing TRAIL could mediate a strong pro-
tection against tumor challenge in syngeneic HSCT recipients, rep-
resenting an ‘‘off the shelf’’ strategy in both allogeneic and
autologous recipients.424
ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION SIG-
NIFICANTLY INCREASES THE RISK OF CHRONIC GRAFT-VERSUS-HOST
DISEASE OF LUNG COMPARED TO BONE MARROW TRANSPLANTATION
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Introduction: Chronic graft versus host disease (GVHD) of lung is
associated with higher transplant related morbidity and mortality af-
ter allogeneic hematopoeitic cell transplant (HCT). Risk factors for
lung GVHD are not yet fully elucidated in detail. We attempted to
identify clinical risk factors for lung GVHD after allogeneic HCT
based on single center experience.
Methods: 401 patients were transplanted between year 2000 and
2007 at the Princess Margaret Hospital, Toronto, Canada. 280
(70%) and 121 (30%) patients received peripheral blood stem cell
(PBSC) and bonemarrow (BM) as a source of stem cells, respectively.
Monitoring with pulmonary function tests (PFT) were performed
prior to transplant, at day 180, then annually. PFT was also
